A.forall is partnering with Nanoform and IMGA to develop and commercialize a new nanoformulated version of encorafenib, an established targeted oncology treatment. The three parties have jointly founded BRAFMed Lda, which will lead clinical development and future outlicensing.
The product, Nanoencorafenib, aims to significantly reduce the pill burden for patients by delivering a higher drugload formulation, enabled by Nanoform’s proprietary technology. A.forall will contribute its development, regulatory and commercial expertise to bring this treatment to market as a value-added medicine.
